HKU Scholars Hub: Browsing DSpace

Browsing by Author Knox, SJ

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 3 to 10 of 10 < previous

	Title	Author(s)	Issue Date	Views
	HBV PGRNA and DNA both rebound immediately following discontinuation of the core inhibitor vebicorvir despite continued nrti treatment in patients with HBeAg positive chronic hepatitis B virus infection: findings from a phase 2 open label study Proceeding/Conference:Oral presentation at the AASLD The Liver Meeting, November 12-15. 2021. Hepatology	Yuen, RMF Ma, XL Hassanein, TI Kwo, PY Ma, J Li, L Kitrinos, K Knox, SJ Stamm, LM Bae, H Sulkowski, MS Elkhashab, M Agarwal, K	2021
	Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection Journal:Journal of Hepatology	Sulkowski, MS Agarwal, K Ma, XL Nguyen, TT Schiff, ER Hann, H-W L Dieterich, DT Nahass, RG Park, JS Chan, S Han, S-H B Gane, EJ Bennett, M Alves, K Evanchik, M Yan, R Huang, Q Lopatin, U Colonno, R Ma, J Knox, SJ Stamm, LM Bonacini, M Jacobson, IM Ayoub, WS Weilert, F Ravendhran, N Ramj, A Kwo, PY Elkhashab, M Hassanein, T Bae, HS Lalezari, JP Fung, SK Yuen, RMF	2022
	Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection Journal:Journal of Hepatology	Yuen, RMF Agarwal, K Ma, XL Nguyen, TT Schiff, ER Hann, H-WL Dieterich, DT Nahass, RT Park, JS Chan, S Han, S-H B Gane, EJ Bennett, M Alves, K Evanchik, M Yan, R Huang, Q Lopatin, U Colonno, R Ma, J Knox, SJ Stamm, LM Bonacini, M Jacobson, IM Ayoub, WS Weilert, F Ravendhran, N Ramji, A Kwo, PY Elkhashab, M Hassanein, T Bae, HS Lalezari, JP Fung, SK Sulkowski, MS	2022
	Safety, pharmacokinetics and antiviral activity of ABI-H2158, a hepatitis B virus core inhibitor: A randomized, placebo-controlled phase 1 study Journal:Journal of Viral Hepatitis	Agarwal, K Xu, J Gane, EJ Nguyen, TT Ding, YH Knox, SJ Alves, K Evanchik, M Zomorodi, K Ma, JL Yan, R Huang, Q Colonno, R Stamm, LM Hassanein, TI Kim, DJ Lim, YS Yuen, MF	12-Jan-2023
	Sofosbuvir and Ledipasvir/Sofosbuvir for the treatment of patients with Chronic Genotype 6 Hepatitis C Virus Infection: integrated analysis of Phase 2 and Phase 3 studies Proceeding/Conference:Hepatology	Gane, EJ Chuang, WL Hassanein, TI Kowdley, KV Lawitz, E Gao, B Mo, H Hyland, RH Yang, JC De-Oertel, S Brainard, DM Knox, SJ McHutchison, JG Lai, CL Chan, HLY	2015
	Sofosbuvir plus ribavirin for 12 16 or 24 weeks results in sustained virologic response over 97% in genotype 1 and 6 HCV infection in Hong Kong Proceeding/Conference:Hepatology International	Lai, CL Yuen, MF Yang, JC Knox, SJ Mo, HM Han, LL Brainard, DM Mchutchison, JG Wong, VWS Chan, HLY	2015	110
	Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong Journal:Alimentary Pharmacology & Therapeutics	Lai, CL Wong, VWS Yuen, RMF Yang, JC Knox, SJ Mo, H Han, LL Brainard, DM Chan, HLY	2016
	Viral response and safety following discontinuation of treatment with the core inhibitor vebicorvir and a nucleos (t)ide reverse transcriptase inhibitor in patients with HBeAg positive or negative chronic hepatitis B virus infection Proceeding/Conference:Journal of Hepatology	Gane, E SulkowskI, M Ma, X Nguyen, T Hann, HW Hassanein, T Elkhashab, M Chan, S Nahass, R Bennett, M Park, J Jacobson, I Bonacini, M Ma, J Yan, R Knox, SJ Stamm, L Ramji, A Han, SHB Ayoub, W Ravendhran, N Kwo, PY Dieterich, D Bae, H Schiff, ER Lalezari, J Fung, S Yuen, RMF	2021

Showing results 3 to 10 of 10 < previous